Gammaglobulin Treatment For Alzheimer's Disease To Be Tested

Researchers will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is traditionally used to treat primary immunodeficiency disorders, but is not currently approved for treating AD, which is one of the leading causes of dementia in the elderly.

Read the whole article on Science Daily

More from Science Daily